Doxovebs
THE HIDDEN POWER
IN ACTION…
Expert's View
Doxorubicin may be used not only as a direct cytotoxic drug against tumor cells, but also as a potent immunomodulatory agent that selectively impairs MDSC-induced immunosuppression, thereby fostering the efficacy of Tâcell-based immunotherapy
Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as.
- Acute lymphoblastic leukemia,
- Acute myeloblastic leukemia,
- Wilms’ tumor,
- Neuroblastoma,
- Soft tissue and bone sarcomas,
- Breast carcinoma,
- Ovarian carcinoma,
- Transitional cell bladder carcinoma,
- Thyroid carcinoma,
- Gastric carcinoma,
- Hodgkin’s disease,
- Malignant lymphoma and
- Bronchogenic carcinoma in which the small cellhistologic type is the most responsive compared to other cell types.
Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.